MedTrace Logo

Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation

NCT01685996 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2018-01-24

Study results available
· View outcomes & findings →

Summary

Randomized trial to evaluate whether zonisamide can enhance varenicline-induced smoking cessation.

Conditions

  • Nicotine Dependence

Interventions

DRUG

zonisamide

In addition to zonisamide vs placebo treatment, varenicline tablets will be dispensed with specific instructions to take at the recommended doses for smoking cessation Participants will receive brief smoking cessation counseling and referral to a quitline

DRUG

placebo

Sponsors & Collaborators

Principal Investigators

  • Annie Umbricht, M.D. · Assistant Professor Behavioral Pharmacology Research Unit The Johns Hopkins University School of Medicine 5510 Nathan Shock Drive Baltimore, MD 21224 tel: 410-550-1917 fax:410-550-0011 [email protected]

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01685996 on ClinicalTrials.gov